AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
ClearVue Technologies Limited (ASX:CPV) has confirmed the quotation of 14,670,426 fully paid ordinary shares issued on 20 July 2026, following a successful and oversubscribed share purchase plan that raised $1.291 million. Shares were priced at $0.088 each, reflecting the lower of a $0.115 cap or a 2.5% discount to the volume-weighted average price over the five trading days before the plan's close. This oversubscription highlights strong investor confidence in ClearVue's strategic direction and provides additional capital to support its operational growth.
Key Highlights
- ClearVue Technologies Limited (CPV) issued 14,670,426 fully paid ordinary shares at $0.088 per share.
- The oversubscribed share purchase plan raised a total of $1.291 million.
- Share price was set at the lower of a $0.115 cap or a 2.5% discount to the five-day VWAP prior to plan closure.
- Shares were issued on 20 July 2026 and have been approved for ASX quotation.
- Post-quotation, ClearVue’s issued capital totals 364,005,606 ordinary shares, alongside various unquoted options and performance rights.
- Listed options linked to the SPP shares on a 1-for-1 basis await shareholder approval at an upcoming general meeting.
Comprehensive Overview of ClearVue’s Oversubscribed Capital Raise via Share Purchase Plan
ClearVue Technologies Limited (ASX:CPV) announced the listing of 14,670,426 ordinary fully paid shares issued under an oversubscribed share purchase plan closed on 20 July 2026. The shares were priced at $0.088 each, generating $1.291 million in proceeds. This capital raise underscores strong market demand and investor endorsement of ClearVue’s strategic initiatives, providing essential funding for ongoing operations and growth.
The issue price was determined by the lower of two valuation methods outlined in the share purchase plan offer: a maximum cap price of $0.115 per share or a 2.5% discount to the volume-weighted average price (VWAP) of shares traded on the ASX during the five trading days leading up to the plan’s close. The oversubscription reflects demand exceeding available shares, signaling positive investor sentiment at the time of the raise.
Pricing Strategy: Cap Price and VWAP Discount Explained
ClearVue’s share purchase plan pricing incorporated a dual-mechanism to balance shareholder interests and fundraising goals. The cap price of $0.115 established a maximum issue price, providing certainty to investors. Concurrently, a 2.5% discount to the five-day VWAP ensured the price reflected recent market activity with a modest investor discount. Ultimately, the lower of these two prices applied, resulting in the $0.088 issue price. This approach is typical in equity raises to combine price certainty with market responsiveness.
Issued Capital and Equity Structure Post-Quotation
Following the issuance and ASX quotation of the new shares, ClearVue’s total ordinary shares on issue stand at 364,005,606. The 14.67 million shares from the share purchase plan represent approximately 4.0% of the post-raise ordinary capital, marking a significant but controlled increase in equity. Alongside quoted shares, ClearVue holds a portfolio of unquoted securities including 25,689,625 options expiring 1 September 2026 at a $0.20 exercise price, multiple option series with exercise prices ranging from nil to $1.00, and 4,000,000 performance rights. These unquoted securities present potential future dilution and form part of the company’s equity incentive and capital management framework.
Shareholder Approval Pending for Listed Options Linked to SPP Shares
The company disclosed that listed options attaching to the share purchase plan shares on a 1-for-1 basis remain subject to shareholder approval at an upcoming general meeting. While the ordinary shares have been issued and quoted, the associated options require explicit shareholder consent before listing and trading on the ASX. This two-step approval process is standard for capital raises involving multiple security components.
If approved, each SPP share would carry one attaching option, potentially adding approximately 14.67 million options to ClearVue’s securities. Shareholders will vote on this proposal at the forthcoming meeting, which will determine whether these options are listed or if the ordinary shares remain the sole securities issued from the plan.
About ClearVue Technologies and Market Positioning
ClearVue Technologies Limited (ASX: CPV, ACN 071397487) specialises in the development and commercialization of advanced glazing and glass technologies. While the update focused on capital raising details, it did not provide specifics on operational activities or geographic reach. The oversubscribed share purchase plan and pricing reflect positive market perceptions of ClearVue’s prospects and strategic direction. Funds raised are expected to support research and development, commercialization, working capital, and strategic investments, reinforcing ClearVue’s capacity to access equity markets on favorable terms.
Investor Distribution and Demand Following Share Issuance
The share purchase plan allotment covered multiple shareholders across various holding sizes. Although the company’s distribution schedule framework was outlined, specific holder counts and percentage breakdowns by shareholding bands were not disclosed. The oversubscription indicates strong participation from existing shareholders, suggesting confidence in the company’s valuation and future outlook. This expanded shareholder base will influence ClearVue’s register and voting dynamics at future meetings.
Regulatory Compliance and ASX Listing Process
ClearVue applied for quotation of the 14,670,426 shares under Appendix 2A of the ASX Listing Rules, which governs securities issued under prior announcements. The proposed issue was initially disclosed in an Appendix 3B announcement dated 22 June 2026 titled "New - Proposed issue of securities - CPV." The recent quotation application finalizes regulatory approval, enabling the shares to trade freely on the ASX from 21 July 2026 onward.
By submitting under Appendix 2A, ClearVue agreed to comply with continuous disclosure obligations. The share purchase plan offer booklet detailed terms, eligibility, and pricing mechanisms binding on the company and participants. The oversubscription and successful quotation demonstrate ClearVue’s effective navigation of regulatory requirements.
Options Portfolio Overview and Potential Shareholder Dilution
ClearVue’s unquoted options portfolio totals approximately 39,329,175 options across multiple series with varying exercise prices and expiry dates. The largest tranche includes 25,689,625 options expiring 1 September 2026 at a $0.20 exercise price, expiring soon after the announcement. Other series include 4,000,000 options expiring 20 February 2029 at $0.30, 989,550 expiring 20 February 2028 at $0.27, and additional tranches with exercise prices up to $1.00. The 4,000,000 performance rights also represent potential equity dilution. Actual dilution depends on future share price performance relative to exercise prices, with higher-strike options unlikely to be exercised unless share prices appreciate significantly.
Timeline and Upcoming Shareholder Decisions
The share purchase plan closed on or before 20 July 2026, with share holdings issued the same day. The ASX quotation was announced on 21 July 2026, completing the process to enable trading of the new shares. The next key event is the general meeting where shareholders will vote on listing the attaching options on a 1-for-1 basis. Approval would add approximately 14.67 million options to ClearVue’s securities, while rejection would leave the ordinary shares as the sole securities issued under the plan.
